An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: Opportunities and challenges in cancer therapy

Journal of Medicinal Chemistry

Volumn 59, Issue 21, 2016, Pages 9575-9598

  Wang, Ying Qing ^a   Wang, Ping Yuan ^a,b   Wang, Yu Ting ^a   Yang, Guang Fu ^b   Zhang, Ao ^a   Miao, Ze Hong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b CENTRAL CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; LACTAM; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TUMOR MARKER; PARP1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL EVALUATION; DNA REPAIR; DRUG BINDING SITE; DRUG DESIGN; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TRANSPORT; GENE MUTATION; HUMAN; LETHALITY; NEOPLASM; NONHUMAN; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; METABOLISM; MOLECULAR MODEL; NEOPLASMS; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84994908887     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00055     Document Type: Review

References (178)

1. Ferraris, D. V. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic J. Med. Chem. 2010, 53, 4561-4584 10.1021/jm100012m
2. Ding, J.; Miao, Z. H.; Meng, L. H.; Geng, M. Y. Emerging cancer therapeutic opportunities target DNA-repair systems Trends Pharmacol. Sci. 2006, 27, 338-344 10.1016/j.tips.2006.04.007
3. He, J. X.; Yang, C. H.; Miao, Z. H. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics Acta Pharmacol. Sin. 2010, 31, 1172-1180 10.1038/aps.2010.103
4. Vyas, S.; Chang, P. New PARP targets for cancer therapy Nat. Rev. Cancer 2014, 14, 502-509 10.1038/nrc3748
5. Morales, J.; Li, L.; Fattah, F. J.; Dong, Y.; Bey, E. A.; Patel, M.; Gao, J.; Boothman, D. A. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases Crit. Rev. Eukaryotic Gene Expression 2014, 24, 15-28 10.1615/CritRevEukaryotGeneExpr.2013006875
6. Benafif, S.; Hall, M. An update on PARP inhibitors for the treatment of cancer OncoTargets Ther. 2015, 8, 519-528 10.2147/OTT.S30793
7. O'Shaughnessy, J.; Osborne, C.; Pippen, J. E.; Yoffe, M.; Patt, D.; Rocha, C.; Koo, I. C.; Sherman, B. M.; Bradley, C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer N. Engl. J. Med. 2011, 364, 205-214 10.1056/NEJMoa1011418
8. Menear, K. A.; Adcock, C.; Boulter, R.; Cockcroft, X. L.; Copsey, L.; Cranston, A.; Dillon, K. J.; Drzewiecki, J.; Garman, S.; Gomez, S.; Javaid, H.; Kerrigan, F.; Knights, C.; Lau, A.; Loh, V. M., Jr; Matthews, I. T.; Moore, S.; O'Connor, M. J.; Smith, G. C. M.; Martin, N. M. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4- fluorobenzyl]-2 H-phthalazin- 1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1 J. Med. Chem. 2008, 51, 6581-6591 10.1021/jm8001263
9. O'Shaughnessy, J.; Schwartzberg, L.; Danso, M. A.; Miller, K. D.; Rugo, H. S.; Neubauer, M.; Robert, N.; Hellerstedt, B.; Saleh, M.; Richards, P.; Specht, J. M.; Yardley, D. A.; Carlson, R. W.; Finn, R. S.; Charpentier, E.; Garcia-Ribas, I.; Winer, E. P. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer J. Clin. Oncol. 2014, 32, 3840-3847 10.1200/JCO.2014.55.2984
10. Novello, S.; Besse, B.; Felip, E.; Barlesi, F.; Mazieres, J.; Zalcman, G.; von Pawel, J.; Reck, M.; Cappuzzo, F.; Ferry, D.; Carcereny, E.; Santoro, A.; Garcia-Ribas, I.; Scagliotti, G.; Soria, J. C. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer Ann. Oncol. 2014, 25, 2156-2162 10.1093/annonc/mdu384
11. Mendeleyev, J.; Kirsten, E.; Hakam, A.; Buki, K. G.; Kun, E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture Biochem. Pharmacol. 1995, 50, 705-714 10.1016/0006-2952(95)00189-7
12. Patel, A. G.; De Lorenzo, S. B.; Flatten, K. S.; Poirier, G. G.; Kaufmann, S. H. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro Clin. Cancer Res. 2012, 18, 1655-1662 10.1158/1078-0432.CCR-11-2890
13. Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Macpherson, E.; Watkins, C.; Carmichael, J.; Matulonis, U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N. Engl. J. Med. 2012, 366, 1382-1392 10.1056/NEJMoa1105535
14. Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C. L.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Fielding, A.; Spencer, S.; Dougherty, B.; Orr, M.; Hodgson, D.; Barrett, J. C.; Matulonis, U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol. 2014, 15, 852-861 10.1016/S1470-2045(14)70228-1
15. Gelmon, K. A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; Yerushalmi, R.; Macpherson, E.; Carmichael, J.; Oza, A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol. 2011, 12, 852-861 10.1016/S1470-2045(11)70214-5
16. Kaufman, B.; Shapira-Frommer, R.; Schmutzler, R. K.; Audeh, M. W.; Friedlander, M.; Balmana, J.; Mitchell, G.; Fried, G.; Stemmer, S. M.; Hubert, A.; Rosengarten, O.; Steiner, M.; Loman, N.; Bowen, K.; Fielding, A.; Domchek, S. M. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation J. Clin. Oncol. 2015, 33, 244-250 10.1200/JCO.2014.56.2728
17. Lynparza Approved in the European Union As First-in-Class Treatment for Advanced BRCA-Mutated Ovarian Cancer; AstraZeneca Global, 18 Dec 2014; http://astrazeneca.com.
18. LYNPARZA Approved by the US Food and Drug Administration for the Treatment of Advanced Ovarian Cancer in Patients with Germline BRCA Mutations; AstraZeneca Global, 19 Dec 2014; http://astrazeneca.com.
19. Lynparza (Olaparib) Granted Breakthrough Therapy Designation by US FDA for Treatment of BRCA1/2 or ATM Gene Mutated Metastatic Castration Resistant Prostate Cancer; AstraZeneca, 28 Jan 2016; http://astrazeneca.com.
20. Miknyoczki, S.; Chang, H.; Grobelny, J.; Pritchard, S.; Worrell, C.; McGann, N.; Ator, M.; Husten, J.; Deibold, J.; Hudkins, R.; Zulli, A.; Parchment, R.; Ruggeri, B. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to Temozolomide and irinotecan but does not potentiate myelotoxicity Mol. Cancer Ther. 2007, 6, 2290-2302 10.1158/1535-7163.MCT-07-0062
21. Lechaftois, M.; Dreano, E.; Palmier, B.; Margaill, I.; Marchand-Leroux, C.; Bachelot-Loza, C.; Lerouet, D. Another ″string to the bow″ of PJ34, a potent poly(ADP-Ribose)polymerase inhibitor: an antiplatelet effect through P2Y12 antagonism? PLoS One 2014, 9, e110776 10.1371/journal.pone.0110776
22. Menear, K. A.; Hummersone, M. G.; Gomez, S.; Javaid, M. H.; Martin, N. M. B.; Kerrigan, F. Phthalazinone derivatives. WO 2009093032, 2009.
23. Awada, A.; Campone, M.; Varga, A.; Aftimos, P.; Frenel, J. S.; Bahleda, R.; Gombos, A.; Bourbouloux, E.; Soria, J. C. An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors Anti-Cancer Drugs 2016, 27, 342-348 10.1097/CAD.0000000000000336
24. Bedikian, A. Y.; Papadopoulos, N. E.; Kim, K. B.; Hwu, W. J.; Homsi, J.; Glass, M. R.; Cain, S.; Rudewicz, P.; Vernillet, L.; Hwu, P. A phase IB trial of intravenous INO-1001 plus oral Temozolomide in subjects with unresectable stage-III or IV melanoma Cancer Invest. 2009, 27, 756-763 10.1080/07357900802709159
25. Thomas, H. D.; Calabrese, C. R.; Batey, M. A.; Canan, S.; Hostomsky, Z.; Kyle, S.; Maegley, K. A.; Newell, D. R.; Skalitzky, D.; Wang, L. Z.; Webber, S. E.; Curtin, N. J. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial Mol. Cancer Ther. 2007, 6, 945-956 10.1158/1535-7163.MCT-06-0552
26. Jones, P.; Wilcoxen, K.; Rowley, M.; Toniatti, C. Niraparib: A Poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination J. Med. Chem. 2015, 58, 3302-3314 10.1021/jm5018237
27. Penning, T. D.; Zhu, G. D.; Gandhi, V. B.; Gong, J.; Liu, X.; Shi, Y.; Klinghofer, V.; Johnson, E. F.; Donawho, C. K.; Frost, D. J.; Bontcheva-Diaz, V.; Bouska, J. J.; Osterling, D. J.; Olson, A. M.; Marsh, K. C.; Luo, Y.; Giranda, V. L. Discovery of the poly (ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1 H-benzimidazole-4- carboxamide (ABT-888) for the treatment of cancer J. Med. Chem. 2009, 52, 514-523 10.1021/jm801171j
28. Wang, B.; Chu, D.; Feng, Y.; Shen, Y.; Aoyagi-Scharber, M.; Post, L. E. Discovery and characterization of (8S, 9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1, 2, 4-triazol-5-yl)-2, 7, 8, 9-tetrahydro-3H-pyrido [4, 3, 2-de] phthalazin-3-one (BMN 673, talazoparib), a novel, highly potent, and orally efficacious poly (ADP-ribose) polymerase-1/2 inhibitor as an anticancer agent J. Med. Chem. 2016, 59, 335-357 10.1021/acs.jmedchem.5b01498
29. Plummer, R.; Dua, D.; Cresti, N.; Suder, A.; Drew, Y.; Prathapan, V.; Stephens, P.; Thornton, J. K.; de las Heras, B.; Ink, B.; Lee, L.; Matijevic, M.; McGrath, S.; Sarker, D. Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma J. Clin. Oncol. 2014, 32 (15 suppl) e19531
30. McGonigle, S.; Chen, Z.; Wu, J.; Chang, P.; Kolber-Simonds, D.; Ackermann, K.; Twine, N. C.; Shie, J. L.; Miu, J. T.; Huang, K. C.; Moniz, G. A.; Nomoto, K. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling Oncotarget 2015, 6, 41307-41323 10.18632/oncotarget.5846
31. BGB-290: PARP1 and PARP2 Inhibitor with Unique Properties; BeiGene: Beijing, 2016; http://www.beigene.com/pipeline/clinical-candidates/bgb-290/.
32. de Jonge, M. J. A.; van Herpen, C.; Gietema, J.; Shepherd, S.; Koornstra, R.; Jager, A.; Den Hollander, M.; Dunbar, M.; Hetman, R.; Serpenti, C.; Xiong, H.; Zhu, M.; Giranda, V. L. 452P A study of ABT-767 in advanced solid tumors with BRCA 1 and BRCA 2 mutations and high grade serous ovarian, fallopian tube, or primary peritoneal cancer Ann. Oncol. 2014, 25 (suppl 4) iv150 10.1093/annonc/mdu331.12
33. Fong, P. C.; Boss, D. S.; Yap, T. A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M. J.; Ashworth, A.; Carmichael, J.; Kaye, S. B.; Schellens, J. H.; de Bono, J. S. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers N. Engl. J. Med. 2009, 361, 123-134 10.1056/NEJMoa0900212
34. Yamamoto, N.; Nokihara, H.; Yamada, Y.; Goto, Y.; Tanioka, M.; Shibata, T.; Yamada, K.; Asahina, H.; Kawata, T.; Shi, X.; Tamura, T. A. A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors Cancer Sci. 2012, 103, 504-509 10.1111/j.1349-7006.2011.02179.x
35. Molife, L. R.; Forster, M. D.; Krebs, M.; Pwint, T.; Middleton, M. R.; Kaye, S. B.; McCormack, P.; Swaisland, H.; Carmichael, J.; Ranson, M. A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors J. Clin. Oncol. 2010, 28 (15 suppl) 2599
36. Bundred, N.; Gardovskis, J.; Jaskiewicz, J.; Eglitis, J.; Paramonov, V.; McCormack, P.; Swaisland, H.; Cavallin, M.; Parry, T.; Carmichael, J.; Dixon, J. M. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery Invest. New Drugs 2013, 31, 949-958 10.1007/s10637-012-9922-7
37. Fong, P. C.; Yap, T. A.; Boss, D. S.; Carden, C. P.; Mergui-Roelvink, M.; Gourley, C.; De Greve, J.; Lubinski, J.; Shanley, S.; Messiou, C.; A'Hern, R.; Tutt, A.; Ashworth, A.; Stone, J.; Carmichael, J.; Schellens, J. H.; de Bono, J. S.; Kaye, S. B. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J. Clin. Oncol. 2010, 28, 2512-2519 10.1200/JCO.2009.26.9589
38. Audeh, M. W.; Carmichael, J.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K. M.; Scott, C.; Weitzel, J. N.; Oaknin, A.; Loman, N.; Lu, K.; Schmutzler, R. K.; Matulonis, U.; Wickens, M.; Tutt, A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 2010, 376, 245-251 10.1016/S0140-6736(10)60893-8
39. Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y.; Amnon, A.; Bell-McGuinn, K. M.; Chen, L. M.; Friedlander, M.; Safra, T.; Vergote, I.; Wickens, M.; Lowe, E. S.; Carmichael, J.; Kaufman, B. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer J. Clin. Oncol. 2012, 30, 372-379 10.1200/JCO.2011.36.9215
40. Tutt, A.; Robson, M.; Garber, J. E.; Domchek, S. M.; Audeh, M. W.; Weitzel, J. N.; Friedlander, M.; Arun, B.; Loman, N.; Schmutzler, R. K.; Wardley, A.; Mitchell, G.; Earl, H.; Wickens, M.; Carmichael, J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 2010, 376, 235-244 10.1016/S0140-6736(10)60892-6
41. Mateo, J.; Carreira, S.; Sandhu, S.; Miranda, S.; Mossop, H.; Perez-Lopez, R.; Nava Rodrigues, D.; Robinson, D.; Omlin, A.; Tunariu, N.; Boysen, G.; Porta, N.; Flohr, P.; Gillman, A.; Figueiredo, I.; Paulding, C.; Seed, G.; Jain, S.; Ralph, C.; Protheroe, A.; Hussain, S.; Jones, R.; Elliott, T.; McGovern, U.; Bianchini, D.; Goodall, J.; Zafeiriou, Z.; Williamson, C. T.; Ferraldeschi, R.; Riisnaes, R.; Ebbs, B.; Fowler, G.; Roda, D.; Yuan, W.; Wu, Y. M.; Cao, X.; Brough, R.; Pemberton, H.; A'Hern, R.; Swain, A.; Kunju, L. P.; Eeles, R.; Attard, G.; Lord, C. J.; Ashworth, A.; Rubin, M. A.; Knudsen, K. E.; Feng, F. Y.; Chinnaiyan, A. M.; Hall, E.; de Bono, J. S. DNA-repair defects and olaparib in metastatic prostate cancer N. Engl. J. Med. 2015, 373, 1697-1708 10.1056/NEJMoa1506859
42. Choy, E.; Butrynski, J. E.; Harmon, D. C.; Morgan, J. A.; George, S.; Wagner, A. J.; D'Adamo, D.; Cote, G. M.; Flamand, Y.; Benes, C. H.; Haber, D. A.; Baselga, J. M.; Demetri, G. D. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy BMC Cancer 2014, 14, 813 10.1186/1471-2407-14-813
43. Lee, J. M.; Hays, J. L.; Annunziata, C. M.; Noonan, A. M.; Minasian, L.; Zujewski, J. A.; Yu, M.; Gordon, N.; Ji, J.; Sissung, T. M.; Figg, W. D.; Azad, N.; Wood, B. J.; Doroshow, J.; Kohn, E. C. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses J. Natl. Cancer Inst. 2014, 106, dju089 10.1093/jnci/dju089
44. Balmaña, J.; Tung, N. M.; Isakoff, S. J.; Graña, B.; Ryan, P. D.; Saura, C.; Lowe, E. S.; Frewer, P.; Winer, E.; Baselga, J.; Garber, J. E. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors Ann. Oncol. 2014, 25, 1656-1663 10.1093/annonc/mdu187
45. Del Conte, G.; Sessa, C.; von Moos, R.; Viganò, L.; Digena, T.; Locatelli, A.; Gallerani, E.; Fasolo, A.; Tessari, A.; Cathomas, R.; Gianni, L. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours Br. J. Cancer 2014, 111, 651-659 10.1038/bjc.2014.345
46. Rajan, A.; Carter, C. A.; Kelly, R. J.; Gutierrez, M.; Kummar, S.; Szabo, E.; Yancey, M. A.; Ji, J.; Mannargudi, B.; Woo, S.; Spencer, S.; Figg, W. D.; Giaccone, G. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors Clin. Cancer Res. 2012, 18, 2344-2351 10.1158/1078-0432.CCR-11-2425
47. Samol, J.; Ranson, M.; Scott, E.; Macpherson, E.; Carmichael, J.; Thomas, A.; Cassidy, J. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study Invest. New Drugs 2012, 30, 1493-1500 10.1007/s10637-011-9682-9
48. Khan, O. A.; Gore, M.; Lorigan, P.; Stone, J.; Greystoke, A.; Burke, W.; Carmichael, J.; Watson, A. J.; McGown, G.; Thorncroft, M.; Margison, G. P.; Califano, R.; Larkin, J.; Wellman, S.; Middleton, M. R. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours Br. J. Cancer 2011, 104, 750-755 10.1038/bjc.2011.8
49. Dent, R. A.; Lindeman, G. J.; Clemons, M.; Wildiers, H.; Chan, A.; McCarthy, N. J.; Singer, C. F.; Lowe, E. S.; Watkins, C. L.; Carmichael, J. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer Breast Cancer Res. 2013, 15, R88 10.1186/bcr3484
50. Rivkin, S. E.; Iriarte, D.; Sloan, H.; Wiseman, C.; Moon, J. Phase Ib/II with expansion of patients at the MTD study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients J. Clin. Oncol. 2014, 32 (15 suppl) 5527
51. Oza, A. M.; Cibula, D.; Benzaquen, A. O.; Poole, C. J.; Mathijssen, R. H. J.; Sonke, G. S.; Colombo, N.; Spacek, J.; Vuylsteke, P.; Hirte, H. W.; Mahner, S.; Plante, M.; Schmalfeldt, B.; Mackay, H.; Rowbottom, J.; Tchakov, I.; Friedlander, M. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study J. Clin. Oncol. 2012, 30 (15 suppl) 5001
52. Bang, Y. J.; Im, S. A.; Lee, K. W.; Cho, J. Y.; Song, E. K.; Lee, K. H.; Kim, Y. H.; Park, J. O.; Chun, H. G.; Zang, D. Y.; Fielding, A.; Rowbottom, J.; Hodgson, D.; O'Connor, M. J.; Yin, X.; Kim, W. H. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer J. Clin. Oncol. 2015, 33, 3858-3865 10.1200/JCO.2014.60.0320
53. Dean, E.; Middleton, M. R.; Pwint, T.; Swaisland, H.; Carmichael, J.; Goodege-Kunwar, P.; Ranson, M. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours Br. J. Cancer 2012, 106, 468-474 10.1038/bjc.2011.555
54. Liu, J. F.; Tolaney, S. M.; Birrer, M.; Fleming, G. F.; Buss, M. K.; Dahlberg, S. E.; Lee, H.; Whalen, C.; Tyburski, K.; Winer, E.; Ivy, P.; Matulonis, U. A. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer Eur. J. Cancer 2013, 49, 2972-2978 10.1016/j.ejca.2013.05.020
55. Liu, J. F.; Barry, W. T.; Birrer, M.; Lee, J. M.; Buckanovich, R. J.; Fleming, G. F.; Rimel, B.; Buss, M. K.; Nattam, S.; Hurteau, J.; Luo, W.; Quy, P.; Whalen, C.; Obermayer, L.; Lee, H.; Winer, E. P.; Kohn, E. C.; Ivy, S. P.; Matulonis, U. A. Combination of cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study Lancet Oncol. 2014, 15, 1207-1214 10.1016/S1470-2045(14)70391-2
56. Matulonis, U.; Wulf, G. M.; Birrer, M. J.; Westin, S. N.; Quy, P.; Bell-McGuinn, K. M.; Lasonde, B.; Whalen, C.; Aghajanian, C.; Solit, D. B.; Mills, G. B.; Cantley, L.; Winer, E. P. Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC) J. Clin. Oncol. 2014, 32 (15 suppl) 2510
57. Campelo, R. G.; Felip, E.; Massuti, B.; Majem, M.; Carcereny, E.; Palmero, R.; Molina-Vila, M. A.; Cajal, R.; Sanchez-Ronco, M.; Rosell, R. Phase Ib study to evaluate the efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) patients J. Clin. Oncol. 2014, 32 (15 suppl) 8079
58. Tang, Z. Y.; Liu, Y.; Zhen, Q.; Ren, B.; Wang, H. X.; Shi, Z. Y.; Gong, We. F.; Liu, Y.; Wang, X.; Gao, Y. J.; Yu, F. L.; Wu, Y. Y.; Jiang, B.; Sun, X. B.; Wei, M.; Zhou, C. Y.; Luo, L. S.; Li, Z. X.; Yu, J. Y.; Zhao, J.; Wang, J.; Wang, L. BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models Cancer Res. 2015, 75, 1653 10.1158/1538-7445.AM2015-1653
59. Russo, A. L.; Kwon, H. C.; Burgan, W. E.; Carter, D.; Beam, K.; Weizheng, X.; Zhang, J.; Slusher, B. S.; Chakravarti, A.; Tofilon, P. J.; Camphausen, K. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016 Clin. Cancer Res. 2009, 15, 607-612 10.1158/1078-0432.CCR-08-2079
60. Shen, Y.; Aoyagi-Scharber, M.; Wang, B. Trapping poly(ADP-Ribose) polymerase J. Pharmacol. Exp. Ther. 2015, 353, 446-457 10.1124/jpet.114.222448
61. Scott, C. L.; Swisher, E. M.; Kaufmann, S. H. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development J. Clin. Oncol. 2015, 33, 1397-1406 10.1200/JCO.2014.58.8848
62. Murai, J.; Huang, S. Y.; Das, B. B.; Renaud, A.; Zhang, Y.; Doroshow, J. H.; Ji, J.; Takeda, S.; Pommier, Y. Trapping of PARP1 and PARP-2 by clinical PARP inhibitors Cancer Res. 2012, 72, 5588-5599 10.1158/0008-5472.CAN-12-2753
63. Murai, J.; Huang, S. Y.; Renaud, A.; Zhang, Y.; Ji, J.; Takeda, S.; Morris, J.; Teicher, B.; Doroshow, J. H.; Pommier, Y. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib Mol. Cancer Ther. 2014, 13, 433-443 10.1158/1535-7163.MCT-13-0803
64. Murai, J.; Zhang, Y.; Morris, J.; Ji, J.; Takeda, S.; Doroshow, J. H.; Pommier, Y. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or Temozolomide based on PARP trapping versus catalytic inhibition J. Pharmacol. Exp. Ther. 2014, 349, 408-416 10.1124/jpet.113.210146
65. Hopkins, T. A.; Shi, Y.; Rodriguez, L. E.; Solomon, L. R.; Donawho, C. K.; DiGiammarino, E. L.; Panchal, S. C.; Wilsbacher, J. L.; Gao, W.; Olson, A. M.; Stolarik, D. F.; Osterling, D. J.; Johnson, E. F.; Maag, D. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors Mol. Cancer Res. 2015, 13, 1465-1477 10.1158/1541-7786.MCR-15-0191-T
66. Montoni, A.; Robu, M.; Pouliot, E.; Shah, G. M. Resistance to PARP-inhibitors in cancer therapy Front. Pharmacol. 2013, 4, 18 10.3389/fphar.2013.00018
67. Ceccaldi, R.; Liu, J. C.; Amunugama, R.; Hajdu, I.; Primack, B.; Petalcorin, M. I.; O'Connor, K. W.; Konstantinopoulos, P. A.; Elledge, S. J.; Boulton, S. J.; Yusufzai, T.; D'Andrea, A. D. Homologous-recombination-deficient tumours are dependent on Pol -mediated repair Nature 2015, 518, 258-262 10.1038/nature14184
68. Mateos-Gomez, P. A.; Gong, F.; Nair, N.; Miller, K. M.; Lazzerini-Denchi, E.; Sfeir, A. Mammalian polymerase promotes alternative NHEJ and suppresses recombination Nature 2015, 518, 254-257 10.1038/nature14157
69. Rodriguez, M. I.; Majuelos-Melguizo, J.; Martí Martín-Consuegra, J. M.; Ruiz de Almodovar, M.; López-Rivas, A.; Javier Oliver, F. Deciphering the insights of poly(ADP-ribosylation) in tumor progression Med. Res. Rev. 2015, 35, 678-697 10.1002/med.21339
70. Ryu, K. W.; Kim, D. S.; Kraus, W. L. New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases Chem. Rev. 2015, 115, 2453-2481 10.1021/cr5004248
71. Rodríguez, M. I.; Peralta-Leal, A.; O'Valle, F.; Rodriguez-Vargas, J. M.; Gonzalez-Flores, A.; Majuelos-Melguizo, J.; López, L.; Serrano, S.; de Herreros, A. G.; Rodríguez-Manzaneque, J. C.; Fernández, R.; Del Moral, R. G.; de Almodóvar, J. M.; Oliver, F. J. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation PLoS Genet. 2013, 9, e1003531 10.1371/journal.pgen.1003531
72. Kraus, W. L.; Hottiger, M. O. PARP-1 and gene regulation: progress and puzzles Mol. Aspects Med. 2013, 34, 1109-1123 10.1016/j.mam.2013.01.005
73. Gunderson, C. C.; Moore, K. N. BRACAnalysis CDx as a companion diagnostic tool for Lynparza Expert Rev. Mol. Diagn. 2015, 15, 1111-1116 10.1586/14737159.2015.1078238
74. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609-615. 10.1038/nature10166
75. Ihnen, M.; zu Eulenburg, C.; Kolarova, T.; Qi, J.; Manivong, K.; Chalukya, M.; Dering, J.; Anderson, L.; Ginther, C.; Meuter, A.; Winterhoff, B.; Jones, S.; Velculescu, V. E.; Venkatesan, N.; Rong, H. M.; Dandekar, S.; Udar, N.; Jänicke, F.; Los, G.; Slamon, D. J.; Konecny, G. E. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer Mol. Cancer Ther. 2013, 12, 1002-1015 10.1158/1535-7163.MCT-12-0813
76. Hartlerode, A. J.; Morgan, M. J.; Wu, Y.; Buis, J.; Ferguson, D. O. Recruitment and activation of the ATM kinase in the absence of DNA-damage sensors Nat. Struct. Mol. Biol. 2015, 22, 736-743 10.1038/nsmb.3072
77. Stracker, T. H.; Petrini, J. H. The MRE11 complex: starting from the ends Nat. Rev. Mol. Cell Biol. 2011, 12, 90-103 10.1038/nrm3047
78. Oplustilova, L.; Wolanin, K.; Mistrik, M.; Korinkova, G.; Simkova, D.; Bouchal, J.; Lenobel, R.; Bartkova, J.; Lau, A.; O'Connor, M. J.; Lukas, J.; Bartek, J. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment Cell Cycle 2012, 11, 3837-3850 10.4161/cc.22026
79. Koppensteiner, R.; Samartzis, E. P.; Noske, A.; von Teichman, A.; Dedes, I.; Gwerder, M.; Imesch, P.; Ikenberg, K.; Moch, H.; Fink, D.; Stucki, M.; Dedes, K. J. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro PLoS One 2014, 9, e100041 10.1371/journal.pone.0100041
80. Vilar, E.; Bartnik, C. M.; Stenzel, S. L.; Raskin, L.; Ahn, J.; Moreno, V.; Mukherjee, B.; Iniesta, M. D.; Morgan, M. A.; Rennert, G.; Gruber, S. B. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers Cancer Res. 2011, 71, 2632-2642 10.1158/0008-5472.CAN-10-1120
81. Faraoni, I.; Compagnone, M.; Lavorgna, S.; Angelini, D. F.; Cencioni, M. T.; Piras, E.; Panetta, P.; Ottone, T.; Dolci, S.; Venditti, A.; Graziani, G.; Lo-Coco, F. BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib Biochim. Biophys. Acta, Mol. Basis Dis. 2015, 1852, 462-472 10.1016/j.bbadis.2014.12.001
82. Weber, A. M.; Ryan, A. J. ATM and ATR as therapeutic targets in cancer Pharmacol. Ther. 2015, 149, 124-138 10.1016/j.pharmthera.2014.12.001
83. Hoglund, A.; Stromvall, K.; Li, Y.; Forshell, L. P.; Nilsson, J. A. Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition Cell Cycle 2011, 10, 3598-3607 10.4161/cc.10.20.17887
84. Gilardini Montani, M. S.; Prodosmo, A.; Stagni, V.; Merli, D.; Monteonofrio, L.; Gatti, V.; Gentileschi, M. P.; Barila, D.; Soddu, S. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition J. Exp. Clin. Cancer Res. 2013, 32, 95 10.1186/1756-9966-32-95
85. Kubota, E.; Williamson, C. T.; Ye, R.; Elegbede, A.; Peterson, L.; Lees-Miller, S. P.; Bebb, D. G. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines Cell Cycle 2014, 13, 2129-2137 10.4161/cc.29212
86. Weston, V. J.; Oldreive, C. E.; Skowronska, A.; Oscier, D. G.; Pratt, G.; Dyer, M. J.; Smith, G.; Powell, J. E.; Rudzki, Z.; Kearns, P.; Moss, P. A.; Taylor, A. M.; Stankovic, T. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo Blood 2010, 116, 4578-4587 10.1182/blood-2010-01-265769
87. Williamson, C. T.; Muzik, H.; Turhan, A. G.; Zamò, A.; O'Connor, M. J.; Bebb, D. G.; Lees-Miller, S. P. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors Mol. Cancer Ther. 2010, 9, 347-357 10.1158/1535-7163.MCT-09-0872
88. Herriott, A.; Tudhope, S. J.; Junge, G.; Rodrigues, N.; Patterson, M. J.; Woodhouse, L.; Lunec, J.; Hunter, J. E.; Mulligan, E. A.; Cole, M.; Allinson, L. M.; Wallis, J. P.; Marshall, S.; Wang, E.; Curtin, N. J.; Willmore, E. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia Oncotarget 2015, 22, 43978-43991 10.18632/oncotarget.6287
89. Wang, Y. Q.; Yan, Q.; Zhang, J. R.; Li, S. D.; Yang, Y. X.; Wan, X. P. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression J. Obstet. Gynaecol. Res. 2013, 39, 549-554 10.1111/j.1447-0756.2012.01979.x
90. Yamashita, N.; Tokunaga, E.; Kitao, H.; Hitchins, M.; Inoue, Y.; Tanaka, K.; Hisamatsu, Y.; Taketani, K.; Akiyoshi, S.; Okada, S.; Oda, Y.; Saeki, H.; Oki, E.; Maehara, Y. Epigenetic inactivation of BRCA1 through promoter hypermethylation and its clinical importance in triple-negative breast cancer Clin. Breast Cancer 2015, 15, 498-504 10.1016/j.clbc.2015.06.009
91. Ruscito, I.; Dimitrova, D.; Vasconcelos, I.; Gellhaus, K.; Schwachula, T.; Bellati, F.; Zeillinger, R.; Benedetti-Panici, P.; Vergote, I.; Mahner, S.; Cacsire-Tong, D.; Concin, N.; Darb-Esfahani, S.; Lambrechts, S.; Sehouli, J.; Olek, S.; Braicu, E. I. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD) Eur. J. Cancer 2014, 50, 2090-2098 10.1016/j.ejca.2014.05.001
92. Jacot, W.; Thezenas, S.; Senal, R.; Viglianti, C.; Laberenne, A. C.; Lopez-Crapez, E.; Bibeau, F.; Bleuse, J. P.; Romieu, G.; Lamy, P. J. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer BMC Cancer 2013, 13, 523 10.1186/1471-2407-13-523
93. Lombardi, A. J.; Hoskins, E. E.; Foglesong, G. D.; Wikenheiser-Brokamp, K. A.; Wiesmüller, L.; Hanenberg, H.; Andreassen, P. R.; Jacobs, A. J.; Olson, S. B.; Keeble, W. W.; Hays, L. E.; Wells, S. I. Acquisition of relative interstrand crosslinker resistance and PARP inhibitor sensitivity in fanconi anemia head and neck cancers Clin. Cancer Res. 2015, 21, 1962-1972 10.1158/1078-0432.CCR-14-2616
94. Duan, W.; Gao, L.; Aguila, B.; Kalvala, A.; Otterson, G. A.; Villalona-Calero, M. A. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer Front. Oncol. 2014, 4, 368 10.3389/fonc.2014.00368
95. Stoepker, C.; Faramarz, A.; Rooimans, M. A.; van Mil, S. E.; Balk, J. A.; Velleuer, E.; Ameziane, N.; Te Riele, H.; de Winter, J. P. DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity DNA Repair 2015, 26, 54-64 10.1016/j.dnarep.2014.12.003
96. Bajrami, I.; Frankum, J. R.; Konde, A.; Miller, R. E.; Rehman, F. L.; Brough, R.; Campbell, J.; Sims, D.; Rafiq, R.; Hooper, S.; Chen, L. N.; Kozarewa, I.; Assiotis, I.; Fenwick, K.; Natrajan, R.; Lord, C. J.; Ashworth, A. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity Cancer Res. 2014, 74, 287-297 10.1158/0008-5472.CAN-13-2541
97. Joshi, P. M.; Sutor, S. L.; Huntoon, C. J.; Karnitz, L. M. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors J. Biol. Chem. 2014, 289, 9247-9253 10.1074/jbc.M114.551143
98. Ip, L. R.; Poulogiannis, G.; Viciano, F. C.; Sasaki, J.; Kofuji, S.; Spanswick, V. J.; Hochhauser, D.; Hartley, J. A.; Sasaki, T.; Gewinner, C. A. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment Oncotarget 2015, 6, 10548-10562 10.18632/oncotarget.3307
99. Salmena, L.; Shaw, P.; Fans, I.; McLaughlin; Rosen, B.; Risch, H.; Mitchell, C.; Sun, P.; Narod, S. A.; Kotsopoulos, J. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer Eur. J. Gynaecol. Oncol. 2015, 36, 260-267
100. Fraser, M.; Zhao, H.; Luoto, K. R.; Lundin, C.; Coackley, C.; Chan, N.; Joshua, A. M.; Bismar, T. A.; Evans, A.; Helleday, T.; Bristow, R. G. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy Clin. Cancer Res. 2012, 18, 1015-1027 10.1158/1078-0432.CCR-11-2189
101. Hunt, C. R.; Gupta, A.; Horikoshi, N.; Pandita, T. K. Does PTEN loss impair DNA double-strand break repair by homologous recombination? Clin. Cancer Res. 2012, 18, 920-922 10.1158/1078-0432.CCR-11-3131
102. Freeman, A. K.; Monteiro, A. N. Phosphatases in the cellular response to DNA damage Cell Commun. Signaling 2010, 8, 27 10.1186/1478-811X-8-27
103. Kalev, P.; Simicek, M.; Vazquez, I.; Munck, S.; Chen, L.; Soin, T.; Danda, N.; Chen, W.; Sablina, A. Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition Cancer Res. 2012, 72, 6414-6424 10.1158/0008-5472.CAN-12-1667
104. Curtis, C.; Shah, S. P.; Chin, S. F.; Turashvili, G.; Rueda, O. M.; Dunning, M. J.; Speed, D.; Lynch, A. G.; Samarajiwa, S.; Yuan, Y.; Gräf, S.; Ha, G.; Haffari, G.; Bashashati, A.; Russell, R.; McKinney, S.; METABRIC Group; Langerød, A.; Green, A.; Provenzano, E.; Wishart, G.; Pinder, S.; Watson, P.; Markowetz, F.; Murphy, L.; Ellis, I.; Purushotham, A.; Børresen-Dale, A. L.; Brenton, J. D.; Tavaré, S.; Caldas, C.; Aparicio, S. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups Nature 2012, 486, 346-352 10.1038/nature10983
105. Mao, X.; Boyd, L. K.; Yáñez-Muñoz, R. J.; Chaplin, T.; Xue, L.; Lin, D.; Shan, L.; Berney, D. M.; Young, B. D.; Lu, Y. J. Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer Am. J. Cancer Res. 2011, 1, 604-617
106. Cousineau, I.; Belmaaza, A. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases Mol. Genet. Genomics 2011, 285, 325-340 10.1007/s00438-011-0612-5
107. Lee, Y. H.; Kuo, C. Y.; Stark, J. M.; Shih, H. M.; Ann, D. K. HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response Nucleic Acids Res. 2013, 41, 5784-5798 10.1093/nar/gkt231
108. Lee, Y. H.; Liu, X.; Qiu, F.; O'Connor, T. R.; Yen, Y.; Ann, D. K. HP1beta is a biomarker for breast cancer prognosis and PARP inhibitor therapy PLoS One 2015, 10, e0121207 10.1371/journal.pone.0121207
109. Sourisseau, T.; Maniotis, D.; McCarthy, A.; Tang, C.; Lord, C. J.; Ashworth, A.; Linardopoulos, S. Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition EMBO Mol. Med. 2010, 2, 130-142 10.1002/emmm.201000068
110. Lord, C. J.; Ashworth, A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers Nat. Med. 2013, 19, 1381-1388 10.1038/nm.3369
111. Feng, F. Y.; Brenner, J. C.; Hussain, M.; Chinnaiyan, A. M. Molecular pathways: targeting ETS gene fusions in cancer Clin. Cancer Res. 2014, 20, 4442-4448 10.1158/1078-0432.CCR-13-0275
112. Brenner, J. C.; Feng, F. Y.; Han, S.; Patel, S.; Goyal, S. V.; Bou-Maroun, L. M.; Liu, M.; Lonigro, R.; Prensner, J. R.; Tomlins, S. A.; Chinnaiyan, A. M. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma Cancer Res. 2012, 72, 1608-1613 10.1158/0008-5472.CAN-11-3648
113. Tang, S. W.; Bilke, S.; Cao, L.; Murai, J.; Sousa, F. G.; Yamade, M.; Rajapakse, V.; Varma, S.; Helman, L. J.; Khan, J.; Meltzer, P. S.; Pommier, Y. SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing sarcoma Clin. Cancer Res. 2015, 21, 4184-4193 10.1158/1078-0432.CCR-14-2112
114. Sandhu, S. K.; Schelman, W. R.; Wilding, G.; Moreno, V.; Baird, R. D.; Miranda, S.; Hylands, L.; Riisnaes, R.; Forster, M.; Omlin, A.; Kreischer, N.; Thway, K.; Gevensleben, H.; Sun, L.; Loughney, J.; Chatterjee, M.; Toniatti, C.; Carpenter, C. L.; Iannone, R.; Kaye, S. B.; de Bono, J. S.; Wenham, R. M. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial Lancet Oncol. 2013, 14, 882-892 10.1016/S1470-2045(13)70240-7
115. Lin, C. H.; Chang, C. Y.; Lee, K. R.; Lin, H. J.; Chen, T. H.; Wan, L. Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway BMC Cancer 2015, 15, 958 10.1186/s12885-015-1965-7
116. Park, S. H.; Jang, K. Y.; Kim, M. J.; Yoon, S.; Jo, Y.; Kwon, S. M.; Kim, K. M.; Kwon, K. S.; Kim, C. Y.; Woo, H. G. Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications Oncotarget 2015, 6 (42) 44819-44831 10.18632/oncotarget.6264
117. Bunting, S. F.; Callén, E.; Wong, N.; Chen, H. T.; Polato, F.; Gunn, A.; Bothmer, A.; Feldhahn, N.; Fernandez-Capetillo, O.; Cao, L.; Xu, X.; Deng, C. X.; Finkel, T.; Nussenzweig, M.; Stark, J. M.; Nussenzweig, A. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks Cell 2010, 141, 243-254 10.1016/j.cell.2010.03.012
118. Jaspers, J. E.; Kersbergen, A.; Boon, U.; Sol, W.; van Deemter, L.; Zander, S. A.; Drost, R.; Wientjens, E.; Ji, J.; Aly, A.; Doroshow, J. H.; Cranston, A.; Martin, N. M.; Lau, A.; O'Connor, M. J.; Ganesan, S.; Borst, P.; Jonkers, J.; Rottenberg, S. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors Cancer Discovery 2013, 3, 68-81 10.1158/2159-8290.CD-12-0049
119. Xu, G.; Chapman, J. R.; Brandsma, I.; Yuan, J.; Mistrik, M.; Bouwman, P.; Bartkova, J.; Gogola, E.; Warmerdam, D.; Barazas, M.; Jaspers, J. E.; Watanabe, K.; Pieterse, M.; Kersbergen, A.; Sol, W.; Celie, P. H.; Schouten, P. C.; van den Broek, B.; Salman, A.; Nieuwland, M.; de Rink, I.; de Ronde, J.; Jalink, K.; Boulton, S. J.; Chen, J.; van Gent, D. C.; Bartek, J.; Jonkers, J.; Borst, P.; Rottenberg, S. REV7 counteracts DNA double-strand break resection and affects PARP inhibition Nature 2015, 521, 541-544 10.1038/nature14328
120. Turner, N. C.; Lord, C. J.; Iorns, E.; Brough, R.; Swift, S.; Elliott, R.; Rayter, S.; Tutt, A. N.; Ashworth, A. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor EMBO J. 2008, 27, 1368-1377 10.1038/emboj.2008.61
121. Bolin, C.; Boudra, M. T.; Fernet, M.; Vaslin, L.; Pennaneach, V.; Zaremba, T.; Biard, D.; Cordelières, F. P.; Favaudon, V.; Mégnin-Chanet, F.; Hall, J. The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation Cell. Mol. Life Sci. 2012, 69, 951-962 10.1007/s00018-011-0811-6
122. Chiker, S.; Pennaneach, V.; Loew, D.; Dingli, F.; Biard, D.; Cordelières, F. P.; Gemble, S.; Vacher, S.; Bieche, I.; Hall, J.; Fernet, M. Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients Cell Cycle 2015, 14, 3066-3078 10.1080/15384101.2015.1078020
123. Chin, K.; DeVries, S.; Fridlyand, J.; Spellman, P. T.; Roydasgupta, R.; Kuo, W. L.; Lapuk, A.; Neve, R. M.; Qian, Z.; Ryder, T.; Chen, F.; Feiler, H.; Tokuyasu, T.; Kingsley, C.; Dairkee, S.; Meng, Z.; Chew, K.; Pinkel, D.; Jain, A.; Ljung, B. M.; Esserman, L.; Albertson, D. G.; Waldman, F. M.; Gray, J. W. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies Cancer Cell 2006, 10, 529-541 10.1016/j.ccr.2006.10.009
124. Ehrlich, S. M.; Liebl, J.; Ardelt, M. A.; Lehr, T.; De Toni, E. N.; Mayr, D.; Brandl, L.; Kirchner, T.; Zahler, S.; Gerbes, A. L.; Vollmar, A. M. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma - A novel therapeutic approach J. Hepatol. 2015, 63, 102-113 10.1016/j.jhep.2015.01.031
125. Huang, E.; Qu, D.; Park, D. S. Cdk5: Links to DNA damage Cell Cycle 2010, 9, 3142-3143 10.4161/cc.9.16.12955
126. Lord, C. J.; Tutt, A. N.; Ashworth, A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors Annu. Rev. Med. 2015, 66, 455-470 10.1146/annurev-med-050913-022545
127. Livraghi, L.; Garber, J. E. PARP inhibitors in the management of breast cancer: current data and future prospects BMC Med. 2015, 13, 188 10.1186/s12916-015-0425-1
128. Bouwman, P.; Jonkers, J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin. Cancer Res. 2014, 20, 540-547 10.1158/1078-0432.CCR-13-0225
129. Drost, R.; Bouwman, P.; Rottenberg, S.; Boon, U.; Schut, E.; Klarenbeek, S.; Klijn, C.; van der Heijden, I.; van der Gulden, H.; Wientjens, E.; Pieterse, M.; Catteau, A.; Green, P.; Solomon, E.; Morris, J. R.; Jonkers, J. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance Cancer Cell 2011, 20, 797-809 10.1016/j.ccr.2011.11.014
130. Moskwa, P.; Buffa, F. M.; Pan, Y.; Panchakshari, R.; Gottipati, P.; Muschel, R. J.; Beech, J.; Kulshrestha, R.; Abdelmohsen, K.; Weinstock, D. M.; Gorospe, M.; Harris, A. L.; Helleday, T.; Chowdhury, D. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors Mol. Cell 2011, 41, 210-220 10.1016/j.molcel.2010.12.005
131. Sun, C.; Li, N.; Yang, Z.; Zhou, B.; He, Y.; Weng, D.; Fang, Y.; Wu, P.; Chen, P.; Yang, X.; Ma, D.; Zhou, J.; Chen, G. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition J. Natl. Cancer Inst. 2013, 105, 1750-1758 10.1093/jnci/djt302
132. Esposito, M. T.; Zhao, L.; Fung, T. K.; Rane, J. K.; Wilson, A.; Martin, N.; Gil, J.; Leung, A. Y.; Ashworth, A.; So, C. W. E. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors Nat. Med. 2015, 21, 1481-1490 10.1038/nm.3993
133. Sun, C. K.; Zhang, F.; Xiang, T.; Chen, Q.; Pandita, T. K.; Huang, Y.; Hu, M. C.; Yang, Q. Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers Oncotarget 2014, 5, 3375-3385 10.18632/oncotarget.1952
134. Volinia, S.; Galasso, M.; Sana, M. E.; Wise, T. F.; Palatini, J.; Huebner, K.; Croce, C. M. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 3024-3029 10.1073/pnas.1200010109
135. Pettitt, S. J.; Rehman, F. L.; Bajrami, I.; Brough, R.; Wallberg, F.; Kozarewa, I.; Fenwick, K.; Assiotis, I.; Chen, L.; Campbell, J.; Lord, C. J.; Ashworth, A. A genetic screen using the PiggyBac transposon in haploid cells identifies PARP1 as a mediator of olaparib toxicity PLoS One 2013, 8, e61520 10.1371/journal.pone.0061520
136. Lawlor, D.; Martin, P.; Busschots, S.; Thery, J.; O'Leary, J. J.; Hennessy, B. T.; Stordal, B. PARP inhibitors as P-glyoprotein substrates J. Pharm. Sci. 2014, 103, 1913-1920 10.1002/jps.23952
137. Henneman, L.; van Miltenburg, M. H.; Michalak, E. M.; Braumuller, T. M.; Jaspers, J. E.; Drenth, A. P.; de Korte-Grimmerink, R.; Gogola, E.; Szuhai, K.; Schlicker, A.; Bin Ali, R.; Pritchard, C.; Huijbers, I. J.; Berns, A.; Rottenberg, S.; Jonkers, J. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 8409-8414 10.1073/pnas.1500223112
138. Jaspers, J. E.; Sol, W.; Kersbergen, A.; Schlicker, A.; Guyader, C.; Xu, G.; Wessels, L.; Borst, P.; Jonkers, J.; Rottenberg, S. BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance Cancer Res. 2015, 75, 732-741 10.1158/0008-5472.CAN-14-0839
139. Dufour, R.; Daumar, P.; Mounetou, E.; Aubel, C.; Kwiatkowski, F.; Abrial, C.; Vatoux, C.; Penault-Llorca, F.; Bamdad, M. BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib Sci. Rep. 2015, 5, 12670 10.1038/srep12670
140. Nakagawa, Y.; Sedukhina, A. S.; Okamoto, N.; Nagasawa, S.; Suzuki, N.; Ohta, T.; Hattori, H.; Roche-Molina, M.; Narváez, A. J.; Jeyasekharan, A. D.; Bernal, J. A.; Sato, K. NF-κB signaling mediates acquired resistance after PARP inhibition Oncotarget 2015, 6, 3825-3839 10.18632/oncotarget.2868
141. + binding to poly (ADP-ribose) polymerase as derived from crystal structures and homology modeling Biochemistry 1998, 37, 3893-3900 10.1021/bi972383s
142. Banasik, M.; Komura, H.; Shimoyama, M.; Ueda, K. Specific inhibitors of poly (ADP-ribose) synthetase and mono (ADP-ribosyl) transferase J. Biol. Chem. 1992, 267, 1569-1575
143. Threadgill, M. D. 5-Aminoisoquinolin-1-one (5-AIQ), a water-soluble inhibitor of the poly(ADP-ribose)polymerases (PARPs) Curr. Med. Chem. 2015, 22, 3807-3829 10.2174/0929867322666151002110602
144. Rottenberg, S.; Jaspers, J. E.; Kersbergen, A.; van der Burg, E.; Nygren, A. O.; Zander, S. A.; Derksen, P. W.; de Bruin, M.; Zevenhoven, J.; Lau, A.; Boulter, R.; Cranston, A.; O'Connor, M. J.; Martin, N. M.; Borst, P.; Jonkers, J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 17079-17084 10.1073/pnas.0806092105
145. Johannes, J. W.; Almeida, L.; Daly, K.; Ferguson, A. D.; Grosskurth, S. E.; Guan, H.; Howard, T.; Ioannidis, S.; Kazmirski, S.; Lamb, M. L.; Larsen, N. A.; Lyne, P. D.; Mikule, K.; Ogoe, C.; Peng, B.; Petteruti, P.; Read, J. A.; Su, N.; Sylvester, M.; Throner, S.; Wang, W.; Wang, X.; Wu, J.; Ye, Q.; Yu, Y.; Zheng, X.; Scott, D. A. Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering Bioorg. Med. Chem. Lett. 2015, 25, 5743-5747 10.1016/j.bmcl.2015.10.079
146. Pescatore, G.; Branca, D.; Fiore, F.; Kinzel, O.; Bufi, L. L.; Muraglia, E.; Orvieto, F.; Rowley, M.; Toniatti, C.; Torrisi, C.; Jones, P. Identification and SAR of novel pyrrolo [1,2-a]pyrazin-1 (2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) Bioorg. Med. Chem. Lett. 2010, 20, 1094-1099 10.1016/j.bmcl.2009.12.026
147. Ferrigno, F.; Branca, D.; Kinzel, O.; Lillini, S.; Bufi, L. L.; Monteagudo, E.; Muraglia, E.; Rowley, M.; Schultz-Fademrecht, C.; Toniatti, C.; Torrisi, C.; Jones, P. Development of substituted 6-[4-fluoro-3- (piperazin-1-ylcarbonyl) benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells Bioorg. Med. Chem. Lett. 2010, 20, 1100-1105 10.1016/j.bmcl.2009.11.087
148. Zhu, G. D.; Gong, J.; Gandhi, V. B.; Liu, X.; Shi, Y.; Johnson, E. F.; Donawho, C. K.; Ellis, P. A.; Bouska, J. J.; Osterling, D. J.; Olson, A. M.; Park, C.; Luo, Y.; Shoemaker, A.; Giranda, V. L.; Penning, T. D. Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer Bioorg. Med. Chem. 2012, 20, 4635-4645 10.1016/j.bmc.2012.06.021
149. Wang, L. X.; Zhou, X. B.; Xiao, M. L.; Jiang, N.; Liu, F.; Zhou, W. X.; Wang, X. K.; Zheng, Z. B.; Li, S. Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1- ones as potent PARP-1 inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 3739-3743 10.1016/j.bmcl.2014.07.001
150. Lapidus, R. G.; Xu, W.; Spicer, E.; Hoover, R.; Zhang, J. PARP inhibitors enhance the effect of cisplatin against tumors and ameliorate cisplatin-induced neuropathy Cancer Res. 2006, 66, 2141
151. Mita, A.; Mita, M.; Sarantopoulos, J.; Martin, J. C.; Kueber, J. D.; McGonigle, S.; Matijevic, M.; Mistry, B.; Ferrada, J. L.; Sachdev, P.; Stephenson, J. J., Jr Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly (ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with Temozolomide (TMZ) in patients with advanced solid tumors Mol. Cancer Ther. 2011, 10 (11 suppl) B185 10.1158/1535-7163.TARG-11-B185
152. Wang, J.; Tan, H.; Sun, Q.; Ge, Z.; Wang, X.; Wang, Y.; Li, R. Design, synthesis and biological evaluation of pyridazino [3, 4, 5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors Bioorg. Med. Chem. Lett. 2015, 25, 2340-2344 10.1016/j.bmcl.2015.04.013
153. Aoyagi-Scharber, M.; Gardberg, A. S.; Yip, B. K.; Wang, B.; Shen, Y.; Fitzpatrick, P. A. Structural basis for the inhibition of poly (ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone Acta Crystallogr., Sect. F: Struct. Biol. Commun. 2014, 70, 1143-1149 10.1107/S2053230X14015088
154. Shen, Y.; Feng, Y.; Wang, B.; Myers, P.; Chu, D.; Post, L. E. Abstract B64: Structure and preclinical characterization of BMN 673, a potent and orally active PARP inhibitor as an anticancer agent Mol. Cancer Ther. 2011, 10 (11 suppl) B64 10.1158/1535-7163.TARG-11-B64
155. de Bono, J. S.; Mina, L. A.; Gonzalez, M.; Curtin, N. J.; Wang, E.; Henshaw, J. W.; Chadha, M.; Sachdev, J. C.; Matei, D.; Jameson, G. S.; Ong, M.; Basu, B.; Wainberg, Z. A.; Byers, L. A.; Chugh, R.; Dorr, A.; Kaye, S. B.; Ramanathan, R. K. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors J. Clin. Oncol. 2013, 31 (15 suppl) 2580
156. Wainberg, Z.; Rafii, S.; Ramanathan, R.; Mina, L.; Byers, L.; Chugh, R.; Goldman, J. W.; Sachsev, J. C.; Matei, D. E.; Wheler, J. J.; Henshaw, J. W.; Zhang, C.; Gallant, G.; de Bono, J. S. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients J. Clin. Oncol. 2014, 32 (15 suppl) 7522
157. Park, C. H.; Chun, K.; Joe, B. Y.; Park, J. S.; Kim, Y. C.; Choi, J. S.; Ryu, D. K.; Koh, S. H.; Cho, G. W.; Kim, S. H.; Kim, M. H. Synthesis and evaluation of tricyclic derivatives containing a non-aromatic amide as inhibitors of poly (ADP-ribose) polymerase-1 (PARP-1) Bioorg. Med. Chem. Lett. 2010, 20, 2250-2253 10.1016/j.bmcl.2010.02.014
158. Gangloff, A. R.; Brown, J.; de Jong, R.; Dougan, D. R.; Grimshaw, C. E.; Hixon, M.; Jennings, A.; Kamran, R.; Kiryanov, A.; O'Connell, S.; Taylor, E.; Vu, P. Discovery of novel benzo [b][1, 4] oxazin-3 (4H)-ones as poly (ADP-ribose) polymerase inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 4501-4505 10.1016/j.bmcl.2013.06.055
159. Chen, J.; Peng, H.; He, J.; Huan, X.; Miao, Z.; Yang, C. Synthesis of isoquinolinone-based tricycles as novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 2669-2673 10.1016/j.bmcl.2014.04.061
160. Ye, N.; Chen, C. H.; Chen, T.; Song, Z.; He, J. X.; Huan, X. J.; Song, S. S.; Liu, Q.; Chen, Y.; Ding, J.; Xu, Y.; Miao, Z. H.; Zhang, A. Design, synthesis, and biological evaluation of a series of benzo [de][1, 7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors J. Med. Chem. 2013, 56, 2885-2903 10.1021/jm301825t
161. Giannini, G.; Battistuzzi, G.; Vesci, L.; Milazzo, F. M.; De Paolis, F.; Barbarino, M.; Guglielmi, M. B.; Carollo, V.; Gallo, G.; Artali, R.; Dallavalle, S. Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold Bioorg. Med. Chem. Lett. 2014, 24, 462-466 10.1016/j.bmcl.2013.12.048
162. Yao, H.; Ji, M.; Zhu, Z.; Zhou, J.; Cao, R.; Chen, X.; Xu, B. Discovery of 1-substituted benzyl-quinazoline-2, 4(1H,3H)-dione derivatives as novel poly (ADP-ribose) polymerase-1 inhibitors Bioorg. Med. Chem. 2015, 23, 681-693 10.1016/j.bmc.2014.12.071
163. Zhou, Q.; Ji, M.; Zhou, J.; Jin, J.; Xue, N.; Chen, J.; Xu, B.; Chen, X. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer Biochem. Pharmacol. 2016, 107, 29-40 10.1016/j.bcp.2016.02.015
164. Zhu, Q.; Wang, X.; Chu, Z.; He, G.; Dong, G.; Xu, Y. Design, synthesis and biological evaluation of novel imidazo[4, 5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 1993-1996 10.1016/j.bmcl.2013.02.032
165. Patel, M. R.; Bhatt, A.; Steffen, J. D.; Chergui, A.; Murai, J.; Pommier, Y.; Pascal, J. M.; Trombetta, L. D.; Fronczek, F. R.; Talele, T. T. Discovery and structure-activity relationship of novel 2, 3-dihydrobenzofuran-7-carboxamide and 2, 3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly (ADP-ribose) polymerase-1 inhibitors J. Med. Chem. 2014, 57, 5579-5601 10.1021/jm5002502
166. Cincinelli, R.; Musso, L.; Merlini, L.; Giannini, G.; Vesci, L.; Milazzo, F. M.; Carenini, N.; Perego, P.; Penco, S.; Artali, R.; Zunino, F.; Pisano, C.; Dallavalle, S. 7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors Bioorg. Med. Chem. 2014, 22, 1089-1103 10.1016/j.bmc.2013.12.031
167. Ishida, J.; Yamamoto, H.; Kido, Y.; Kamijo, K.; Murano, K.; Miyake, H.; Ohkubo, M.; Kinoshita, T.; Warizaya, M.; Iwashita, A.; Mihara, K.; Matsuoka, N.; Hattori, K. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling Bioorg. Med. Chem. 2006, 14, 1378-1390 10.1016/j.bmc.2005.09.061
168. Eltze, T.; Boer, R.; Wagner, T.; Weinbrenner, S.; McDonald, M. C.; Thiemermann, C.; Bürkle, A.; Klein, T. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly (ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors Mol. Pharm. 2008, 74, 1587-1598 10.1124/mol.108.048751
169. Pellicciari, R.; Camaioni, E.; Costantino, G.; Formentini, L.; Sabbatini, P.; Venturoni, F.; Eren, G.; Bellocchi, D.; Chiarugi, A.; Moroni, F. On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives ChemMedChem 2008, 3, 914-923 10.1002/cmdc.200800010
170. Sunderland, P. T.; Woon, E. C.; Dhami, A.; Bergin, A. B.; Mahon, M. F.; Wood, P. J.; Jones, L. A.; Tully, S. R.; Lloyd, M. D.; Thompson, A. S.; Javaid, H.; Martin, N. M.; Threadgill, M. D. 5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl) isoquinolin-1-ones as isoform-selective inhibitors of poly (ADP-ribose) polymerase 2 (PARP-2) J. Med. Chem. 2011, 54, 2049-2059 10.1021/jm1010918
171. Papeo, G.; Posteri, H.; Borghi, D.; Busel, A. A.; Caprera, F.; Casale, E.; Ciomei, M.; Cirla, A.; Corti, E.; D'Anello, M.; Fasolini, M.; Forte, B.; Galvani, A.; Isacchi, A.; Khvat, A.; Krasavin, M. Y.; Lupi, R.; Orsini, P.; Perego, R.; Pesenti, E.; Pezzetta, D.; Rainoldi, S.; Riccardi-Sirtori, F.; Scolaro, A.; Sola, F.; Zuccotto, F.; Felder, E. R.; Donati, D.; Montagnoli, A. Discovery of 2-[1-(4,4-difluorocyclohexyl) piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4- carboxamide (NMS-P118): A potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy J. Med. Chem. 2015, 58, 6875-6898 10.1021/acs.jmedchem.5b00680
172. Pearl, L. H.; Schierz, A. C.; Ward, S. E.; Al-Lazikani, B.; Pearl, F. M. Therapeutic opportunities within the DNA damage response Nat. Rev. Cancer 2015, 15, 166-180 10.1038/nrc3891
173. Wahlberg, E.; Karlberg, T.; Kouznetsova, E.; Markova, N.; Macchiarulo, A.; Thorsell, A. G.; Pol, E.; Frostell, A.; Ekblad, T.; Öncü, D.; Kull, B.; Robertson, G. M.; Pellicciari, R.; Schüler, H.; Weigelt, J. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors Nat. Biotechnol. 2012, 30, 283-288 10.1038/nbt.2121
174. Boehler, C.; Gauthier, L.; Yelamos, J.; Noll, A.; Schreiber, V.; Dantzer, F. Phenotypic characterization of Parp-1 and Parp-2 deficient mice and cells Methods Mol. Biol. 2011, 780, 313-336 10.1007/978-1-61779-270-0-19
175. Poruchynsky, M. S.; Komlodi-Pasztor, E.; Trostel, S.; Wilkerson, J.; Regairaz, M.; Pommier, Y.; Zhang, X.; Kumar Maity, T.; Robey, R.; Burotto, M.; Sackett, D.; Guha, U.; Fojo, A. T. Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 1571-1576 10.1073/pnas.1416418112
176. Chan, N.; Bristow, R. G. ″Contextual″ synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair Clin. Cancer Res. 2010, 16, 4553-4560 10.1158/1078-0432.CCR-10-0527
177. Rosell, R.; Molina, M. A.; Costa, C.; Simonetti, S.; Gimenez-Capitan, A.; Bertran-Alamillo, J.; Mayo, C.; Moran, T.; Mendez, P.; Cardenal, F.; Isla, D.; Provencio, M.; Cobo, M.; Insa, A.; Garcia-Campelo, R.; Reguart, N.; Majem, M.; Viteri, S.; Carcereny, E.; Porta, R.; Massuti, B.; Queralt, C.; de Aguirre, I.; Sanchez, J. M.; Sanchez-Ronco, M.; Mate, J. L.; Ariza, A.; Benlloch, S.; Sanchez, J. J.; Bivona, T. G.; Sawyers, C. L.; Taron, M. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations Clin. Cancer Res. 2011, 17, 1160-1168 10.1158/1078-0432.CCR-10-2158
178. Hegan, D. C.; Lu, Y.; Stachelek, G. C.; Crosby, M. E.; Bindra, R. S.; Glazer, P. M. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130 Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 2201-2206 10.1073/pnas.0904783107